Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin in serious mycobacterial infections
NCT03164291Phase 3Completed
- Sponsor
- The University of Texas Health Science Center at Tyler
- Start
- Jun 1984
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rifabutin in Mycobacterium avium complex lung infection, Tuberculosis (TB) and nontuberculous mycobacterial infection (NTM), sponsored by The University of Texas Health Science Center at Tyler. Primary endpoint: Clinical and microbiological outcomes at 6 months. Started Jun 1984; status: completed.
02
Drugs
rifabutin
03
Conditions
Mycobacterium avium complex lung infectionTuberculosis (TB)nontuberculous mycobacterial infection (NTM)
Beyond the preview
Go deeper on NCT03164291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164291.